Repatha Reviewers
Executive Summary
FDA staff involved in review of Amgen's PCSK9 inhibitor evolocumab for reducing LDL-cholesterol.
You may also be interested in...
Repatha Was Almost Derailed By Formulation Bridging Concerns
FDA's worries about sufficiency of long-term safety data were exacerbated by 'weak' bridging data between two formulations; agency decided against refuse-to-file action but directed Amgen to immediately begin new PK/PD study.
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
2020 In Review: US FDA New Drug Office’s COVID-19 Response Aided By Reorganization
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: